Does asthma affect morbidity or severity of COVID-19? - 22/07/20
Doi : 10.1016/j.jaci.2020.05.017
Kenji Matsumoto, MD, PhD ⁎ 
, Hirohisa Saito, MD, PhD
, Hirohisa Saito, MD, PhD Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan
∗Corresponding author: Kenji Matsumoto, MD, PhD, Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.Department of Allergy and Clinical ImmunologyNational Research Institute for Child Health and Development2-10-1 OkuraSetagaya-kuTokyo157-8535Japan
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Key words : Coronavirus disease 2019, asthma, angiotensin-converting enzyme 2, IFN, T2 cytokines
Il testo completo di questo articolo è disponibile in PDF.
| This work was supported in part by a grant from the National Center for Child Health and Development of Japan (grant no. 2020B-4 to K.M.). |
|
| Disclosure of potential conflicts of interest: The authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 146 - N° 1
P. 55-57 - Luglio 2020 Ritorno al numero
Articolo precedente
- Update on JACI’s evolution
- Zuhair K. Ballas
- Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective
- Lennart Hammarström, Hassan Abolhassani, Fausto Baldanti, Harold Marcotte, Qiang Pan-Hammarström
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.